| Name | APX-115 |
| Description | APX-115 (Ewha-18278) (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor (Kis: 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4). APX-115 effectively prevents kidney injury. |
| In vitro | In the mouse podocyte cell line, APX-115 (5 μM; 60 min) almost completely suppresses high glucose-induced proinflammatory and profibrotic molecule expression. In the kidney, APX-115 attenuates Nox gene upregulation and protein expression while improving inflammatory and fibrotic processes [2]. |
| In vivo | APX-115 treatment decreases the urinary excretion of albumin and plasma creatinine levels. APX-115 (oral gavage; 60 mg/kg/day; for 12 weeks) significantly improves insulin resistance in diabetic mice[1]. |
| Storage | 02 | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (10.45 mM), Sonication is recommended. DMSO : 90 mg/mL (284.99 mM), Sonication is recommended.
|
| Keywords | Nox4 | Nox2 | Nox1 | NADPHoxidase | APX-115 | APX115 | APX 115 |
| Inhibitors Related | ML171 | Melamine | Metronidazole | Ketoconazole | Pasiniazid | 2-Methoxy-4-ethylphenol | Dicoumarol | NAD+ | Apocynin | Triclosan | AKR1C1-IN-1 | 6-Aminonicotinamide |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Diabetic Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |